A1 and B1, as HDAC6 inhibitors, not only exhibited significant anti-tumor activity in leukemia cells but reduced the release of inflammatory cytokines such as IL-6, TNF-α, and IL-1β, thereby decreasing inflammatory responses. Here, IL6 is linked to leukemia.